Biomea Fusion to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, will participate in two investor conferences in early December 2025.
Key events: Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 in New York, with a fireside chat at 8:00 AM ET and one-on-one meetings; and Evercore 8th Annual Healthcare Conference on December 3, 2025 in Coral Gables, with a fireside chat at 7:30 AM ET and one-on-one meetings. An audio webcast and a replay will be available via Biomea Fusion's News & Events page under Investors & Media.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BMEA gained 2.85%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $66M at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcoming investor conferences:
- Piper Sandler 37th Annual Healthcare Conference: Biomea will participate in a fireside chat at 8:00 AM (EST) and in one-on-one meetings on December 2, 2025 in New York, NY.
- 8th Annual Evercore Healthcare Conference: Biomea will participate in a Fireside Chat at 7:30 AM (EST) and in one-on-one meetings on December 3, 2025 in Coral Gables, FL.
An audio webcast of the presentations will be available here or by visiting the News & Events Page under the Investors & Media section of Biomea’s website. A replay of the webcasts will be available following the live event.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies for diabetes and obesity; icovamenib, a selective menin inhibitor for diabetes and BMF-650, a next generation oral GLP-1 receptor agonist for obesity. These programs target cardio metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
When will Biomea Fusion (BMEA) present at the Piper Sandler conference?
What time is Biomea Fusion's fireside chat at the Evercore Healthcare Conference (BMEA)?
How can investors watch Biomea Fusion (BMEA) presentations from the conferences?
Will Biomea Fusion (BMEA) hold one-on-one meetings at the December 2025 conferences?
What is Biomea Fusion's business focus mentioned for the December 2025 investor conferences?
